Suchergebnisse - "Rochette, Samuel"

PubPharm (23)

1

Development and use of a method based on the anti-N reactivity of longitudinal samples to better estimate SARS-CoV-2 seroprevalence in a vaccinated population

enthalten in: bioRxiv.org | 2023

von Bazin, R. | Rochette, S. | Perreault, J. | +6

2

Incidence of acute haemolytic transfusion reaction among ABO-incompatible recipients transfused with A3 blood : A case series

enthalten in: Vox sanguinis | 2023

von Latour, C. | Gaussen, A. | Beaudoin, J. | +3

3

Cohort Profile: Prospective Cohort to Study the COVID-19 Immune Response in Retail Workers in Québec, Canada (CISACOV)

enthalten in: bioRxiv.org | 2023

von Santerre, K. | Thériault, M. | Brousseau, N. | +7

4

Transmission of Variant Creutzfeldt-Jakob Disease Through Blood Transfusion and Plasma-Derived Products : A Narrative Review of Observed and Modeled Risks

enthalten in: Transfusion medicine reviews | 2023

von Pozzo di Borgo, A. | Rochette, S. | Gaussen, A. | +4

5

Prevalence of weak D phenotypes in the general population of Québec, Canada : A focus on weak D type 42

enthalten in: Vox sanguinis | 2023

von Drouin, M. | Rochette, S. | St-Louis, M. | +2

6

Evaluation of anti-nucleocapsid level variation to assess SARS-CoV-2 seroprevalence in a vaccinated population

enthalten in: Infectious diseases (London, England) | 2023

von Bazin, R. | Rochette, S. | Perreault, J. | +6

CommentIn: Infect Dis (Lond). 2023 Jun;55(6):446. - PMID 37102358

7

Cost-effectiveness of pathogen reduction technology for plasma and platelets in Québec : A focus on potential emerging pathogens

enthalten in: Transfusion | 2022

von Grégoire, Y. | Delage, G. | Custer, B. | +4

8

Cost‐effectiveness of pathogen reduction technology for plasma and platelets in Québec : A focus on potential emerging pathogens

enthalten in: Transfusion | 2022

von Grégoire, Y. | Delage, G. | Custer, B. | +4

9

Author Correction : Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins

enthalten in: Scientific reports | 2021

von Hojjat Jodaylami, M. | Djaïleb, A. | Ricard, P. | +16

ErratumFor: Sci Rep. 2021 Nov 8;11(1):21601. - PMID 34750399

10

Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins

enthalten in: Scientific reports | 2021

von Hojjat Jodaylami, M. | Djaïleb, A. | Ricard, P. | +16

ErratumIn: Sci Rep. 2021 Nov 19;11(1):22912. - PMID 34799675